Voydeya Receives FDA Approval as Supplemental Treatment with Ravulizumab or Eculizumab for Managing Extravascular Hemolysis in Adult Patients with PNH
Voydeya (danicopan) has received approval in the United States for use alongside ravulizumab or eculizumab in treating extravascular hemolysis (EVH) in adults diagnosed with paroxysmal nocturnal hemoglobinuria (PNH). This innovative oral Factor D inhibitor, Voydeya, is the first of its kind and is designed to complement the standard treatments Ultomiris (ravulizumab) or Soliris (eculizumab). Its purpose is to cater to the needs of the roughly 10-20% of PNH patients who undergo clinically significant EVH despite being...
